 |
| PubMed trend for published papers on siRNA |
Gene
therapy is a hot topic in both genetics and pharmacology. It involves
exploiting genetic pathways to treat disease by replacing a mutated gene,
integrating a new gene, knocking a gene out, or silencing a gene. "This
allows for an entirely new platform of drug targets outside of traditional
small molecule targets such as enzymes and receptors. Among the most prominent of these methods is
gene silencing, a field in research and medicine that has started to come into
its own and show results clinically. The method I will be discussing here -
gene silencing via the use of small interfering RNA (siRNA) - requires small
pieces of RNA that complement the mRNA transcript of the targeted gene in order
to disable or "silence" expression of the gene.
Figure 1: "Gene
Silencing by Design" Chemical and Engeering News,
November 18, 2013 https://cen.acs.org/articles/91/i46/Gene-Silencing-Design.html
siRNAs
are administered as double-stranded RNAs, and then cleaved by endonucleases
into single-stranded RNAs (Fig. 1). One of these strands is simply a
"passenger" strand that is released and plays no further role. The
other strand is the siRNA itself, a fragment of 21-25 nucleotides engineered to
be complimentary to the messenger RNA (mRNA) of the targeted gene (Gavrilov
& Saltzman, 2012). The siRNA interacts with key proteins such as DICER (an
RNA-cleaving endoribonuclease) and Ago-2 (an RNA-binding protein which can
mediate RNA degradation) to form a complex called the RNA-Induced Silencing
Complex (RISC). When the siRNA, as part of the RISC complex, binds the target
mRNA, the mRNA is cleaved. The cleaved mRNA is thus incomplete and
non-functional, and will not be translated into protein (Lam, Chow, Zhang,
& Leung, 2015). The transcription of the gene, therefore, does not serve
its biological purpose and is functionally "silenced".
The
clinical applications of siRNA-based treatments are extensive. As of July of
2021, there are three siRNA-based drugs which have been approved by FDA with several
being tested in clinical trials (Fig. 2). The first to be approved was
Patisiran, an siRNA drug approved to treat transthyretin-mediated amyloidosis
(hATTR). hATTR is caused by mutations in the gene coding for the transthyretin
protein, which causes amyloid deposition in the central nervous system (CNS),
heart, kidneys, and GI tract, leading to severe neuropathy, heart disease, and
ulimately death. The siRNA drug disrupts expression of this protein, and
significantly alleviates symptoms. The second siRNA drug approved for clinical
use by the FDA was Givosiran. Givosiran is used as a treatment for acute
hepatic porphyria (AHP), which causes accumulation of neurotoxic metabolites,
leading to symptoms such as seizures, muscle weakness, tachycardia, and
paralysis. Givosiran disrupts expression of the ALAS1 gene, reducing
AHP-related "attacks" by 74% in clinical trials. Finally, the most
recent FDA-approved drug was Lumasiran, which hit the market in November of
2020. Lumasiran is used to treat primary hyperoxaluria type 1 (PH1), a disease
associated with hepatic enzyme deficiency and toxic metabolite accumulation.
The primary symptom of the disease is excessive calcium oxalate forming kidney
stones, leading to severe damage of the renal system and potential death due to
systemic accumulation of oxalate. Lumasiran targets the gene transcript
associated with a protein which synthesizes the precursor to oxalate, providing
a 53-65% reduction in oxalate levels. Several drugs are currently being tested
in clinical trials for their potential to treat a variety of diseases,
including other hepatic diseases, familial hypercholesterolemia, hemophilia,
kidney disease, glaucoma, and others (Zhang, Bahal, Rasmussen, Manautou, &
Zhong, 2021).
Clearly,
siRNA therapeutics are a promising avenue in pharmacological research which
have begun to realize their potential after gaining the interest of the
biomedical research community in the late 1990's/early 2000's (Fig. 3). The
results are impressive, and even more so is the fact that many of these
treatments exhibit effects lasting months following a single treatment, due to
the ability of the RISC to protect siRNAs from degradation (Kim, 2020). The
merits of siRNA drugs are beginning to yield great advancements in gene
therapy, and the number of siRNA- based products on the market is expected to
grow significantly in the next decade. Clinical use of siRNA therapeutics is
still in its infancy, but its role in the future of medicine is sure to be
prominent.
By
Henry Snider, A Master’s of Medical Science Student at the University of
Kentucky
References
Borman,
S. (2013). Gene Silencing by Design. Chemical & Engineering News, 91(46).
Gavrilov,
K., & Saltzman, W. M. (2012). Therapeutic siRNA: principles, challenges,
and strategies. Yale J Biol Med, 85(2), 187-200.
Kim,
Y. K. (2020). RNA Therapy: Current Status and Future Potential. Chonnam Med J,
56(2), 87-93. doi:10.4068/cmj.2020.56.2.87
Lam,
J. K., Chow, M. Y., Zhang, Y., & Leung, S. W. (2015). siRNA Versus miRNA as
Therapeutics for Gene Silencing. Mol Ther Nucleic Acids, 4, e252.
doi:10.1038/mtna.2015.23
Zhang,
M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X. B. (2021).
The growth of siRNA-based
therapeutics: Updated clinical studies. Biochem Pharmacol, 189, 114432. doi:10.1016/j.bcp.2021.114432